You probably know the feeling of staring at a pharmacy receipt and wondering why the price is so high. Many Americans split pills or skip doses because the cost adds up. For tens of millions on Medicaid, that math is about to shift.
On September 18, 2026, the White House announced that all 50 state Medicaid programs have signed on to a new drug pricing deal. According to the White House fact sheet, the deal caps what Medicaid pays for hundreds of brand name medicines.
The agreement uses what the administration calls Most-Favored-Nation pricing. In plain words, Medicaid will not pay more for a given brand name drug than the lowest price any other wealthy country pays for the same product.
How the deal actually reaches your prescription
The program runs through a new federal payment model called GENEROUS. The Centers for Medicare and Medicaid Services says the model launched in January 2026 and will run for five years. Rebates are retroactive to January 1, 2026 for manufacturers that joined.
Also read: The US government just doubled how much protein you should eat each day
Drug makers pay quarterly rebates back to each state. States then share those savings with the federal government under the usual Medicaid matching formula. The sticker price at the counter stays the same, but the net cost to the public system drops.
For most people on Medicaid, copays are already very low, often a few dollars for a brand name drug. The headline shift for enrollees is not a smaller receipt. It is extra state money and a wider list of drugs the program can afford to cover.
At the announcement, President Donald Trump argued every state would gain from the deal and could redirect the billions saved into other healthcare priorities.
Which companies signed and what the list covers
The deals name 26 drug makers, including Pfizer, Eli Lilly, Novo Nordisk, Merck, Johnson & Johnson, AbbVie, Sanofi and GSK. The fact sheet says the agreements cover hundreds of individual drugs across virtually all major drug classes.
Also read: Two meals had the same calories but ultra-processed foods had a surprisingly different effect
Oncology drugs, diabetes care and asthma medicines are called out as areas of focus.
The scale is wide. According to KFF, 73.2 million people were enrolled in Medicaid and CHIP as of June 2026.
The policy rests on a familiar argument. Executive Order 14297 notes that the US holds less than five percent of the world's population. Yet it funds roughly three quarters of global pharmaceutical profits.
What the critics are watching
Not everyone is convinced the savings will land as advertised. Independent policy analysts have noted that the exact drugs and prices in the agreements have not been made public, which makes outside verification difficult.
Also read: Why 15 million teens are now vaping, and WHO points to the flavors on the shelf
The deals also rest on voluntary commitments from manufacturers. Policy watchers have warned there is no guarantee the lower prices stay in place after the current administration leaves office.
The GENEROUS Model is scheduled to run through December 31, 2030, and the full list of drugs covered under each manufacturer deal has not yet been published.
Also read: Scientists find depression has 5 distinct brain patterns, and each may need a different treatment
This article is made and published by Aksel Kryhlmand, who may have used AI in the preparation.